Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug;36(4):259-73.
doi: 10.1007/s10935-015-0394-3.

Estimated Human and Economic Burden of Four Major Adult Vaccine-Preventable Diseases in the United States, 2013

John M McLaughlin  1 , Justin J McGinnis, Litjen Tan, Annette Mercatante, Joseph Fortuna
Affiliations

Estimated Human and Economic Burden of Four Major Adult Vaccine-Preventable Diseases in the United States, 2013

John M McLaughlin et al. J Prim Prev. 2015 Aug.

Abstract

Low uptake of routinely recommended adult immunizations is a public health concern. Using data from the peer-reviewed literature, government disease-surveillance programs, and the US Census, we developed a customizable model to estimate human and economic burden caused by four major adult vaccine-preventable diseases (VPD) in 2013 in the United States, and for each US state individually. To estimate the number of cases for each adult VPD for a given population, we multiplied age-specific incidence rates obtained from the literature by age-specific 2013 Census population data. We then multiplied the estimated number of cases for a given population by age-specific, estimated medical and indirect (non-medical) costs per case. Adult VPDs examined were: (1) influenza, (2) pneumococcal disease (both invasive disease and pneumonia), (3) herpes zoster (shingles), and (4) pertussis (whooping cough). Sensitivity analyses simulated the impact of various epidemiological scenarios on the total estimated economic burden. Estimated US annual cost for the four adult VPDs was $26.5 billion (B) among adults aged 50 years and older, $15.3B (58 %) of which was attributable to those 65 and older. Among adults 50 and older, influenza, pneumococcal disease, herpes zoster, and pertussis made up $16.0B (60 %), $5.1B (19 %), $5.0B (19 %), and $0.4B (2 %) of the cost, respectively. Among those 65 and older, they made up $8.3B (54 %), $3.8B (25 %), $3.0B (20 %), and 0.2B (1 %) of the cost, respectively. Most (80-85 %) pneumococcal costs stemmed from nonbacteremic pneumococcal pneumonia (NPP). Cost attributable to adult VPD in the United States is substantial. Broadening adult immunization efforts beyond influenza only may help reduce the economic burden of adult VPD, and a pneumococcal vaccination effort, primarily focused on reducing NPP, may constitute a logical starting place. Sensitivity analyses revealed that a pandemic influenza season or change in size of the US elderly population could increase these costs dramatically.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Percentage of total estimated annual number of cases and overall cost of four major adult vaccine-preventable disease in the United States, 2013 for adults aged a 50 years and older. b 65 years and older
See this image and copyright information in PMC

References

    1. American Lung Association. (2010). Trends in pneumonia and influenza morbidity and mortality: American lung association research and program services epidemiology and statistics unit.
    1. Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, Grobbee DE. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. New England Journal of Medicine. 2015;372(12):1114–1125. doi: 10.1056/NEJMoa1408544. - DOI - PubMed
    1. Centers for Disease Control and Prevention Influenza and pneumococcal vaccination levels among persons aged ≥65 years—United States, 2001. MMWR. Morbidity and Mortality Weekly Report. 2002;51(45):1019–1024. - PubMed
    1. Centers for Disease Control and Prevention Interim results: State-specific seasonal influenza vaccination coverage—United States, August 2009-January 2010. MMWR. Morbidity and Mortality Weekly Report. 2010;59(16):477–484. - PubMed
    1. Centers for Disease Control and Prevention Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR. Morbidity and Mortality Weekly Report. 2011;60(1):13–15. - PubMed

Publication types

MeSH terms

LinkOut - more resources